Aberrant methylation of imprinted genes is associated with negative hormone receptor status in invasive breast cancer

Timothy M. Barrow, Ludovic Barault, Rachel E. Ellsworth, Holly R. Harris, Alexandra M. Binder, Allyson L. Valente, Craig D. Shriver, Karin B. Michels

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Epigenetic regulation of imprinted genes enables monoallelic expression according to parental origin, and its disruption is implicated in many cancers and developmental disorders. The expression of hormone receptors is significant in breast cancer because they are indicators of cancer cell growth rate and determine response to endocrine therapies. We investigated the frequency of aberrant events and variation in DNA methylation at nine imprinted sites in invasive breast cancer and examined the association with estrogen and progesterone receptor status. Breast tissue and blood from patients with invasive breast cancer (n = 38) and benign breast disease (n = 30) were compared with those from healthy individuals (n = 36), matched with the cancer patients by age at diagnosis, ethnicity, body mass index, menopausal status and familial history of cancer. DNA methylation and allele-specific expression were analyzed by pyrosequencing. Tumor-specific methylation changes at IGF2 DMR2 were observed in 59% of cancer patients, IGF2 DMR0 in 38%, DIRAS3 DMR in 36%, GRB10 ICR in 23%, PEG3 DMR in 21%, MEST ICR in 19%, H19 ICR in 18%, KvDMR in 8% and SNRPN/SNURF ICR in 4%. Variation in methylation was significantly greater in breast tissue from cancer patients compared with that in healthy individuals and benign breast disease. Aberrant methylation of three or more sites was significantly associated with negative estrogen-alpha (Fisher's exact test, p = 0.02) and progesterone-A (p = 0.02) receptor status. Aberrant events and increased variation in imprinted gene DNA methylation, therefore, seem to be frequent in invasive breast cancer and are associated with negative estrogen and progesterone receptor status, without loss of monoallelic expression.

Original languageEnglish
Pages (from-to)537-547
Number of pages11
JournalInternational Journal of Cancer
Volume137
Issue number3
DOIs
Publication statusPublished - Aug 1 2015

Fingerprint

Methylation
Hormones
Breast Neoplasms
DNA Methylation
Genes
Neoplasms
Breast Diseases
Progesterone Receptors
Estrogen Receptors
snRNP Core Proteins
Epigenomics
Progesterone
Estrogens
Breast
Body Mass Index
Alleles
Growth

Keywords

  • breast cancer
  • DNA methylation
  • genomic imprinting
  • hormone receptor
  • pyrosequencing

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Aberrant methylation of imprinted genes is associated with negative hormone receptor status in invasive breast cancer. / Barrow, Timothy M.; Barault, Ludovic; Ellsworth, Rachel E.; Harris, Holly R.; Binder, Alexandra M.; Valente, Allyson L.; Shriver, Craig D.; Michels, Karin B.

In: International Journal of Cancer, Vol. 137, No. 3, 01.08.2015, p. 537-547.

Research output: Contribution to journalArticle

Barrow, TM, Barault, L, Ellsworth, RE, Harris, HR, Binder, AM, Valente, AL, Shriver, CD & Michels, KB 2015, 'Aberrant methylation of imprinted genes is associated with negative hormone receptor status in invasive breast cancer', International Journal of Cancer, vol. 137, no. 3, pp. 537-547. https://doi.org/10.1002/ijc.29419
Barrow, Timothy M. ; Barault, Ludovic ; Ellsworth, Rachel E. ; Harris, Holly R. ; Binder, Alexandra M. ; Valente, Allyson L. ; Shriver, Craig D. ; Michels, Karin B. / Aberrant methylation of imprinted genes is associated with negative hormone receptor status in invasive breast cancer. In: International Journal of Cancer. 2015 ; Vol. 137, No. 3. pp. 537-547.
@article{c433305d49ab42a2bd338c5b707074eb,
title = "Aberrant methylation of imprinted genes is associated with negative hormone receptor status in invasive breast cancer",
abstract = "Epigenetic regulation of imprinted genes enables monoallelic expression according to parental origin, and its disruption is implicated in many cancers and developmental disorders. The expression of hormone receptors is significant in breast cancer because they are indicators of cancer cell growth rate and determine response to endocrine therapies. We investigated the frequency of aberrant events and variation in DNA methylation at nine imprinted sites in invasive breast cancer and examined the association with estrogen and progesterone receptor status. Breast tissue and blood from patients with invasive breast cancer (n = 38) and benign breast disease (n = 30) were compared with those from healthy individuals (n = 36), matched with the cancer patients by age at diagnosis, ethnicity, body mass index, menopausal status and familial history of cancer. DNA methylation and allele-specific expression were analyzed by pyrosequencing. Tumor-specific methylation changes at IGF2 DMR2 were observed in 59{\%} of cancer patients, IGF2 DMR0 in 38{\%}, DIRAS3 DMR in 36{\%}, GRB10 ICR in 23{\%}, PEG3 DMR in 21{\%}, MEST ICR in 19{\%}, H19 ICR in 18{\%}, KvDMR in 8{\%} and SNRPN/SNURF ICR in 4{\%}. Variation in methylation was significantly greater in breast tissue from cancer patients compared with that in healthy individuals and benign breast disease. Aberrant methylation of three or more sites was significantly associated with negative estrogen-alpha (Fisher's exact test, p = 0.02) and progesterone-A (p = 0.02) receptor status. Aberrant events and increased variation in imprinted gene DNA methylation, therefore, seem to be frequent in invasive breast cancer and are associated with negative estrogen and progesterone receptor status, without loss of monoallelic expression.",
keywords = "breast cancer, DNA methylation, genomic imprinting, hormone receptor, pyrosequencing",
author = "Barrow, {Timothy M.} and Ludovic Barault and Ellsworth, {Rachel E.} and Harris, {Holly R.} and Binder, {Alexandra M.} and Valente, {Allyson L.} and Shriver, {Craig D.} and Michels, {Karin B.}",
year = "2015",
month = "8",
day = "1",
doi = "10.1002/ijc.29419",
language = "English",
volume = "137",
pages = "537--547",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Aberrant methylation of imprinted genes is associated with negative hormone receptor status in invasive breast cancer

AU - Barrow, Timothy M.

AU - Barault, Ludovic

AU - Ellsworth, Rachel E.

AU - Harris, Holly R.

AU - Binder, Alexandra M.

AU - Valente, Allyson L.

AU - Shriver, Craig D.

AU - Michels, Karin B.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Epigenetic regulation of imprinted genes enables monoallelic expression according to parental origin, and its disruption is implicated in many cancers and developmental disorders. The expression of hormone receptors is significant in breast cancer because they are indicators of cancer cell growth rate and determine response to endocrine therapies. We investigated the frequency of aberrant events and variation in DNA methylation at nine imprinted sites in invasive breast cancer and examined the association with estrogen and progesterone receptor status. Breast tissue and blood from patients with invasive breast cancer (n = 38) and benign breast disease (n = 30) were compared with those from healthy individuals (n = 36), matched with the cancer patients by age at diagnosis, ethnicity, body mass index, menopausal status and familial history of cancer. DNA methylation and allele-specific expression were analyzed by pyrosequencing. Tumor-specific methylation changes at IGF2 DMR2 were observed in 59% of cancer patients, IGF2 DMR0 in 38%, DIRAS3 DMR in 36%, GRB10 ICR in 23%, PEG3 DMR in 21%, MEST ICR in 19%, H19 ICR in 18%, KvDMR in 8% and SNRPN/SNURF ICR in 4%. Variation in methylation was significantly greater in breast tissue from cancer patients compared with that in healthy individuals and benign breast disease. Aberrant methylation of three or more sites was significantly associated with negative estrogen-alpha (Fisher's exact test, p = 0.02) and progesterone-A (p = 0.02) receptor status. Aberrant events and increased variation in imprinted gene DNA methylation, therefore, seem to be frequent in invasive breast cancer and are associated with negative estrogen and progesterone receptor status, without loss of monoallelic expression.

AB - Epigenetic regulation of imprinted genes enables monoallelic expression according to parental origin, and its disruption is implicated in many cancers and developmental disorders. The expression of hormone receptors is significant in breast cancer because they are indicators of cancer cell growth rate and determine response to endocrine therapies. We investigated the frequency of aberrant events and variation in DNA methylation at nine imprinted sites in invasive breast cancer and examined the association with estrogen and progesterone receptor status. Breast tissue and blood from patients with invasive breast cancer (n = 38) and benign breast disease (n = 30) were compared with those from healthy individuals (n = 36), matched with the cancer patients by age at diagnosis, ethnicity, body mass index, menopausal status and familial history of cancer. DNA methylation and allele-specific expression were analyzed by pyrosequencing. Tumor-specific methylation changes at IGF2 DMR2 were observed in 59% of cancer patients, IGF2 DMR0 in 38%, DIRAS3 DMR in 36%, GRB10 ICR in 23%, PEG3 DMR in 21%, MEST ICR in 19%, H19 ICR in 18%, KvDMR in 8% and SNRPN/SNURF ICR in 4%. Variation in methylation was significantly greater in breast tissue from cancer patients compared with that in healthy individuals and benign breast disease. Aberrant methylation of three or more sites was significantly associated with negative estrogen-alpha (Fisher's exact test, p = 0.02) and progesterone-A (p = 0.02) receptor status. Aberrant events and increased variation in imprinted gene DNA methylation, therefore, seem to be frequent in invasive breast cancer and are associated with negative estrogen and progesterone receptor status, without loss of monoallelic expression.

KW - breast cancer

KW - DNA methylation

KW - genomic imprinting

KW - hormone receptor

KW - pyrosequencing

UR - http://www.scopus.com/inward/record.url?scp=84929507363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929507363&partnerID=8YFLogxK

U2 - 10.1002/ijc.29419

DO - 10.1002/ijc.29419

M3 - Article

C2 - 25560175

AN - SCOPUS:84929507363

VL - 137

SP - 537

EP - 547

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -